Bajaj Healthcare Posts ₹42.03 Cr Profit; Announces ₹1 Per Share Final Dividend
By Ankur Chandra | Updated at: May 31, 2025 10:41 PM IST
Thane | May 27, 2025 – Bajaj Healthcare Ltd (BSE: 539872, NSE: BAJAJHCARE) announced its financial results for the year and delivered a strong performance. The company also declared a final dividend of ₹1 per equity share.
Financial Highlights – FY25 vs FY24
| Particulars | FY25 (₹ lakh) | FY24 (₹ lakh) | YoY Change |
|---|---|---|---|
| Revenue from Operations | 54,260.24 | 47,341.79 | +14.6% |
| Other Income | 1,940.44 | 868.63 | +123.4% |
| Total Income | 56,200.68 | 48,210.42 | +16.6% |
| Total Expenses | 51,599.91 | 45,445.16 | +13.6% |
| Profit Before Tax (PBT) | 4,600.77 | (11,667.55) | Turnaround |
| Net Profit / (Loss) | 4,202.88 | (14,379.31) | Turnaround |
| EPS (Basic) | ₹13.29 | ₹(30.36) | – |
| Total Comprehensive Income | ₹4,086.56 | ₹(8,656.87) | – |
Quarterly Performance – Q4 FY25 (vs Q4 FY24)
- Revenue from operations grew 15.3% YoY to ₹15,447.25 lakh in Q4 FY25.
- Net profit stood at ₹1,159.30 lakh, as against a loss of ₹3,200.05 lakh in Q4 FY24.
Discontinued Operations
The company recorded a loss of ₹343.33 lakh due to factors such as discontinued operations for FY25 when compared to a higher loss of ₹6,946.65 lakh in FY24.
Balance Sheet Overview (₹ in lakh)
| Particulars | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|
| Total Assets | 83,304.62 | 76,512.77 |
| Equity (Share Capital + Reserves) | 46,616.42 | 27,836.09 |
| Total Liabilities | 36,688.20 | 48,676.68 |
| Cash & Cash Equivalents | 260.38 | 217.47 |
| Trade Receivables | 25,167.42 | 18,024.00 |
Notable movements:
- The company increased its long-term borrowings to ₹6,466.51 lakh (from ₹3,857.81 lakh).
- The company reduced its short-term borrowings to ₹15,795.91 lakh (from ₹29,349.12 lakh).
- The company’s other equity rose to ₹45,037.26 lakh from ₹26,456.17 lakh.
Corporate Actions & Appointments
- Final Dividend: ₹1.00 per share (20%) recommended for FY25.
- Funding: Raised ₹14,969.75 lakh through equity and share warrants in FY25.
- Appointments:
- Internal Auditor: Re-appointed M/s V J Shah & Co. for FY26.
- Cost Auditor: Re-appointed M/s V.J. Talati & Co. for FY26.
- Secretarial Auditor: Appointed Mr. Haresh Sanghvi for FY26–FY30.
Management & Outlook
The company announced that the auditor’s report was released without any changes (unmodified), which means that the company’s accounts were clean. Furthermore, the company has seen strong financial growth due to factors such as operational discipline, strategic divestment of non-core assets, and reduced dependence on short-term debt. It also acquired Genrx Pharmaceuticals to improve its business.
Recent Dividend History:
- FY25: ₹1.00 (Recommended)
- FY24: ₹1.00
- FY23: ₹1.00
About the Company
Bajaj Healthcare Limited is an Indian company that manufactures drugs in bulk and serves multiple industries. The company was established in 1993 and is headquartered in Thane, Maharashtra. The company is listed on both BSE and NSE.
REF: https://nsearchives.nseindia.com/corporate/BAJAJHCARE_26052025193506_BMOutcome.pdf
